Annals of allergy.
A review of the world literature regarding the relative efficacy, duration and toxicity of the available beta-adrenergic bronchodilator aerosols for the treatment of asthma is presented. Many of these agents will soon become available in the United States and some familiarity with their actions is necessary for optimal care of asthmatic patients.
D000318:Adrenergic beta-Agonists; D000336:Aerosols / Q000009:adverse effects; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D004837:Epinephrine / Q000627:therapeutic use; D005280:Fenoterol / Q000627:therapeutic use; D006594:Hexoprenaline / Q000627:therapeutic use; D007545:Isoproterenol / Q000627:therapeutic use; D009921:Metaproterenol / Q000627:therapeutic use; D010101:Oxygen Consumption; D011941:Receptors, Adrenergic; D013726:Terbutaline / Q000627:therapeutic use; D014213:Tretoquinol / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000336:Aerosols; D011941:Receptors, Adrenergic; D005280:Fenoterol; D009921:Metaproterenol; D006594:Hexoprenaline; D014213:Tretoquinol; D007545:Isoproterenol; D013726:Terbutaline; D000420:Albuterol; D004837:Epinephrine